Forest Laboratories and Hungary's Gedeon Richter says that high doses of its antipsychotic drug failed to demonstrate a statistically significant response in a Phase IIb trial, but low doses of RGH-188 reflected "nominally" significant results. Research will continue to determine if the therapy can work as a treatment for schizophrenia. A full set of data will be released in a few weeks, when analysts can get a better idea of what "nominally statistically significant" means.
- see the release for more information
Related Articles:
New schizophrenia drugs no better than generic. Report
Lilly's schizophrenia drug may offer breakthrough. Report
Forest Labs dumps failed stroke drug program. Report
Mice engineer to be schizophrenic. Report
Read more on: Forest Labs | Schizophrenia